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Corticosteroids exert antiemetic effects as single drugs and
enhance the effects of other antiemetics such as benzamides and
5-HT3 receptor antagonists (Blazon and Zorzano-Estrade, 1987;
Hawthorn and Cunningham, 1990; Stephens et al, 1990). The
mechanism of action whereby corticosteroids affect nausea is not
understood. Possible mechanisms of action have been suggested:
¥ modified capillary permeability of the CNS and reduced expo-
sure of emetic trigger sites to toxic stimuli (Livera et al, 1985);
¥ reduced levels of 5-HT in neural tissue by depletion of its
precursor, tryptophan (Young, 1981);
¥ the anti-inflammatory properties of cortisol may prevent the
release of serotonin in the gut or prevent activation of 5-HT
receptors in the gastrointestinal system (Fredrikson et al,
1992);
¥ sensitization of the 5-HT3 receptor (Sagar, 1991).
For antiemetic prophylaxis, 20 mg of dexamethasone or its
equivalent appears to be the gold-standard dose and most
commonly used in routine antiemetic prophylaxis as well as clin-
ical trials. However, concern about the use of corticosteroids has
been expressed because of the possibility of enhanced tumour
growth (Haid, 1981), higher incidence of distant tumour (Sherlock
and Hartmann, 1962), or impaired killing of the tumour cells
(Powell et al, 1990). In in vitro experiments, the addition of corti-
costeroids did not reduce the anti-tumoral effect of cisplatinum
(Aapro and Alberts, 1981). In contrast, corticosteroids are impor-
tant components of many antineoplastic regimens, especially
haematological malignancies, or are required to reduce the side-
effects of some cytotoxic agents such as taxanes. But the problem
still remains unsolved.
To the best of our knowledge, there have been no earlier investi-
gations on the importance of dexamethasone dosage in antiemetic
therapy. Earlier studies have mainly investigated different corti-
costeroid quantities in comparison with no or placebo medication.
Prior work in this area suggests that especially patients with
low prechemotherapy night-time cortisol excretion profit from
cortisol administration (Fredrickson et al, 1992), that endogenous
cortisol exerts antiemetic effects similar to that of exogenous corti-
costeroids (Hursti et al, 1993), and dexamethasone in high doses
(20 mg) may impair the control of delayed symptoms (Peterson et
al, 1996) whereas this adverse effect was not observed at doses of
8 mg (Carmichael et al, 1994).
To study benefits and side-effects of single high-dose dexa-
methasone (20 mg) in comparison to single medium-dose dexa-
methasone (8 mg), we started this prospective, randomized,
single-blind trial. Satisfactory antiemetic control was also
observed with 8 mg dexamethasone in other trials.
PATIENTS AND METHODS
Sixty-nine patients assigned to receive either PEC (cis-platinum
50 mg m—2, epirubicin 60 mg m—2 and cyclophosphamide 500 mg
m—2) or PTx (cis-platinum 75 mg m—2 and paclitaxel 175 mg m—2)
combination chemotherapy on 1 day in the first line on an in-
patient basis upon histologically confirmed ovarian cancer were
enrolled in this single-blind, prospective trial. Patients with CNS
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Correspondence to: K Münstedtmetastases, malfunction of liver, kidney or heart, subileus or ileus
in their history, allergy against 5-HT3 antagonists and/or aliza-
pride, drug and alcohol abuse, nausea and emesis with no correla-
tion to chemotherapy, anticipatory nausea and vomiting, more than
five vomiting episodes in a preceding cycle of chemotherapy, and
concomitant corticosteroid medication were primarily excluded
from the trial. Patients￿ characteristics are listed in Table 1. In case
of patients who were not chemotherapy naive, all of them had
20 mg of dexamethasone on the same chemotherapy protocol as
before. Patients (n = 52) were allowed to participate in the study
twice, receiving the opposite alternative of antiemetic prophylaxis
at the second time. Seventeen patients received only one course of
chemotherapy, either because of failure of the antiemetic prophyl-
axis or end or change of chemotherapy. Stratification was carried
out using a randomization list according to planned chemotherapy,
the number of preceding chemotherapy courses and experiences
with nausea and emesis (e.g. hyperemesis gravidarum). The alter-
natives for prophylaxis of acute nausea and vomiting were:
(a) dexamethasone (Fortecortin, Merck, Germany; 20 mg) plus
tropisetron (Navoban, Novartis, Germany; 5 mg); or (b) dexa-
methasone (8 mg) plus tropisetron (5 mg).
Patients were allowed normal food and drink intake before
chemotherapy. Beginning at about 08:00 h, patients received 1 l of
P￿D-II solution (Fresenius, Germany) intravenously until either
(a) or (b) antiemetic prophylaxis was given 30 min before chemo-
therapy at about 12:00 h. Food intake was not permitted until 8 h
after chemotherapy. Until the next morning, all patients received an
additional 1 l of P￿D-II solution and 2 l of saline intravenously. In
case of five or more vomiting episodes on the day of chemotherapy,
patients received triflupromazine suppositories (70 mg, Psyquil,
Sanifi Winthrop) as a rescue medication. These patients were
excluded from participation in the study a second time.
During days 2—4, all patients received alizapride (Vergentan,
Synthelabo, Germany; 3 ´ 100 mg) orally for prophylaxis of
delayed nausea and vomiting, which has proven efficacy
(M￿nstedt et al, 1995). During their stay in the hospital over the
entire study period, patients completed a self-report diary daily, in
which the number of vomiting and retching episodes were
recorded. A retching or vomiting episode was defined to have
ended when at least 1 min had passed since retching or vomiting
ceased. Wellbeing, including nausea, was assessed on the same
basis using a translated version of the Rotterdam Symptom
Checklist (de Haes et al, 1990).
Data analyses were carried out using the Wilcoxon and
Mann—Whitney  U-tests; and Kruskal—Wallis analysis with the help
of the testimate 5.1 and SPSS for Windows 7.0 computer programs.
RESULTS
Objective parameters
No significant differences were observed between both groups
during the observation period from day 0 to day 5 with respect to
objective parameters, which included absolute number of vomiting
and retching episodes and their distribution during the day, bowel
movement and food intake. Figure 1 shows the similar distribution
of objective vomiting on the day of chemotherapy in both groups.
Subjective parameters
Either treatment alternative of 20 mg or of 8 mg dexamethasone had
no statistically significant influence on subjective parameters,
including nausea, of the Rotterdam Symptom Checklist (de Haes et
al, 1990) during the observation period. Both antiemetic regimens
were well tolerated. Of the patients in group A, 64.8% compared
with 82.1% of group B considered efficacy and tolerability of the
antiemetic prophylaxis to be good or very good. Of group A patients,
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Table 1 Criteria for inclusion and exclusion
Criteria for inclusion in this study
Histologically proven ovarian cancer, abdominal carcinoma, or cancer of
the fallopian tube
Treatment with PEC or PTx – combination chemotherapy
Informed consent
Criteria for exclusion
CNS metastases
Malfunction of liver, kidney or heart
Subileus or ileus in patients’ history
Allergy against 5-HT3 antagonists and/or alizapride
Drug and alcohol abuse
Nausea and emesis with no correlation to chemotherapy
Anticipatory nausea and vomiting
More than five vomiting episodes in a preceding cycle of chemotherapy
Concomitant corticosteroid medication
Table 2 Patients’ characteristics
Group A (20 mg) Group B (8 mg)
(%) (%)
Age
<40 1.9 0
41–50 9.3 11.9
51–60 18.5 22.4
61–70 59.3 47.8
>70 11.1 17.9
FIGO stage
I 14.8 19.4
II 18.5 19.4
III 51.9 46.3
IV 14.8 14.9
Preceding courses of chemotherapy
0 40.2 40.3
1 27.3 28.4
<4 20.0 22.4
<7 12.5 8.9
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Figure 1 Relative frequency of number of vomiting episodes. Complete
response (0 vomiting episodes); major control (1 or 2 vomiting episodes);
minor control (3–5 vomiting episodes); or failure (>5 vomiting episodes).
Group A (20 mg dexamethasone, n); group B (8 mg dexamethasone,  )75.9% expressed a desire to receive the same medication in a poten-
tial next course of chemotherapy compared with 82.1% in group B.
Because this interim analysis after 121 courses of chemotherapy
failed to show a major benefit of either dexamethasone dose, we
decided to discontinue the study because of the lack of later clin-
ical relevance of the results. We believe that, for a final conclusion
on the subject, a prospective, randomized, double-blinded study
would be more appropriate.
DISCUSSION
To the best of our knowledge, there have been no earlier trials
evaluating the importance of dexamethasone dosage in antiemetic
prophylaxis. Trials using either dose have been published
(Campora et al, 1994; Carmichael et al, 1994). The benefit of addi-
tional corticosteroid therapy to 5-HT3 antagonists is undisputed.
As already mentioned above, there is controversy about the safety
of corticosterid administration as an antiemetic substance in cancer
chemotherapy in non-haematological malignancies in which corti-
costeroids are not generally administered.
This study failed to prove a clinical advantage of high-dose
dexamethasone (20 mg) over medium-dose dexamethasone (8 mg)
in combination with tropisetron for prophylaxis of acute nausea
and vomiting. Referring to the work of Peterson et al (1996), we
were also unable to detect differences between the control of
delayed symptoms. Perhaps impaired control of delayed symp-
toms is a sequel of corticosteroid administration for prophylaxis of
acute nausea and vomiting.
As a compromise between unknown risks and proven benefits,
we believe that corticosteroid usage should be handled reluctantly,
which applies to both the use in general as well as the required
doses. The lowest effective corticosteroid dose should be chosen
until further studies provide more knowledge on this topic. Doses
equivalent to 8 mg dexamethasone seem to be appropriate at the
present time because this study failed to demonstrate a significant
clinically relevant difference between high and moderate dexam-
ethasone treatment. Perhaps even smaller doses may be sufficient,
which will be a topic of future investigations.
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